Company Description
Sanara MedTech Inc., a medical technology company, develops, markets, and distributes surgical, wound, and skincare products and services to physicians, hospitals, clinics, and post-acute care settings in the United States.
The company offers CellerateRX Surgical, a medical hydrolysate of Type I bovine collagen indicated for the management of surgical, traumatic, and partial- and full-thickness wounds, as well as first- and second-degree burns; and HYCOL, a medical hydrolysate of Type I bovine collagen intended for the management of full and partial thickness wounds, including pressure ulcers, venous and arterial leg ulcers, and diabetic foot ulcers.
It also provides BIAKŌS Antimicrobial Skin and Wound Cleanser, a patented product that contains synergistic ingredients that have been shown to impact mature biofilm microbes; BIAKŌS Antimicrobial Wound Gel, an antimicrobial hydrogel wound dressing that helps against planktonic microbes, as well as immature and mature biofilms; and BIAKŌS Antimicrobial Skin and Wound Irrigation Solution.
In addition, it develops BIASURGE, a no-rinse surgical solution used for wound irrigation; FORTIFY TRG, a freeze-dried, multi-layer small intestinal submucosa extracellular matrix sheet; FORTIFY FLOWABLE extracellular matrix, an advanced wound care device; TEXAGEN, a multi-layer amniotic membrane allograft used as an anatomical barrier with robust handling that can be sutured for securement; and VIM Amnion Matrix, a homologous wound covering product.
Sanara MedTech Inc. was incorporated in 2001 and is based in Fort Worth, Texas.
| Country | United States |
| Founded | 1982 |
| Industry | Medical Instruments & Supplies |
| Sector | Healthcare |
| Employees | 108 |
| CEO | Ronald T. Nixon |
Contact Details
Address: 1200 Summit Ave, Suite 414 Fort Worth, Texas 76102 United States | |
| Phone | 817-529-2300 |
| Website | sanaramedtech.com |
Stock Details
| Ticker Symbol | SMTI |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0000714256 |
| CUSIP Number | 79957L100 |
| ISIN Number | US79957L1008 |
| Employer ID | 59-2220004 |
| SIC Code | 3842 |
Key Executives
| Name | Position |
|---|---|
| Zachary B. Fleming | Chief Executive Officer |
| Ronald T. Nixon | Executive Chairman |
| Michael D. McNeil | Chief Financial Officer and Corporate Secretary |
| Dr. Christopher A. Morrison FACHM, FAPWCA, FCCWS, M.D. | President of Telehealth Services |
| Callon Nichols | Vice President of Corporate Operations |
| Bill Fitzgerald | Chief Compliance Officer |
| Tricia Matteson | Vice President of Marketing |
| Tyler Palmer | Chief Corporate Development and Strategy Officer |
| Dr. Rebecca Erin Mcmahon | President of Research and Development |
| Seth Yon | President of Commercial |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jun 20, 2024 | 8-K | Current Report |
| Jun 18, 2024 | 8-K | Current Report |
| Jun 17, 2024 | 8-K | Current Report |
| May 31, 2024 | EFFECT | Notice of Effectiveness |
| May 30, 2024 | 8-K | Current Report |
| May 28, 2024 | UPLOAD | Filing |
| May 21, 2024 | S-3 | Registration statement under Securities Act of 1933 |
| May 15, 2024 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| May 15, 2024 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| May 13, 2024 | 10-Q | Quarterly Report |